The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Leont'ev S.G.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Mironov A.V.

NII SP im. N.V. Sklifosovskogo

Ustinov F.S.

Gorodskaia klinicheskaia bol'nitsa #1 im. N.I. Pirogova, Moskva

Complications of thrombolythic therapy of massive pulmonary embolism

Authors:

Leont'ev S.G., Mironov A.V., Ustinov F.S.

More about the authors

Journal: Journal of Venous Disorders. 2013;7(1): 55‑61

Views: 8090

Downloaded: 109

Download PDF (RU)
Contact the author
Table of contents

COMPLICATIONS OF THROMBOLYTHIC THERAPY OF MASSIVE PULMONARY EMBOLISM
COMPLICATIONS OF THROMBOLYTHIC THERAPY OF MASSIVE PULMONARY EMBOLISM

To cite this article:

Leont'ev SG, Mironov AV, Ustinov FS. Complications of thrombolythic therapy of massive pulmonary embolism. Journal of Venous Disorders. 2013;7(1):55‑61. (In Russ.)

Подписка 2025-2 (Journal of Venous Disorders)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Embo­lic Risk of Deep Vein Thro­mbosis is not Rela­ted to the Nature of Proximal Clot. Journal of Venous Diso­rders. 2024;(2):115-121
Embo­lic Risk of Deep Vein Thro­mbosis is not Rela­ted to the Nature of Proximal Clot. Journal of Venous Diso­rders. 2024;(2):115-121
Anti­coagulant Therapy Flaws in Hospitalized Patients with Proximal Deep Vein Thro­mbosis and Their Impact on the Treatment Outcomes. Journal of Venous Diso­rders. 2024;(3):178-184
Mini­mally inva­sive inte­rventions for complications asso­ciated with intra-abdominal calculi after lapa­roscopic cholecystectomy. Piro­gov Russian Journal of Surgery. 2024;(5):14-20
The resu­lts of clinical application of the mesh with anti-adhesive fluoropolymer coating in lapa­roscopic intraperitoneal repair of primary ventral hernia. Piro­gov Russian Journal of Surgery. 2024;(5):86-94
Reco­nstructive plastic surgery in combined treatment of breast cancer: predictive risk factors of complications and reco­nstruction failure. P.A. Herzen Journal of Onco­logy. 2024;(3):13-19
Surgical treatment of traumatic arte­riovenous fistulas of extremities. Piro­gov Russian Journal of Surgery. 2024;(7):92-102
Role of acute kidney injury in the treatment of acute lower limb ischemia. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(4):457-462
Hypoalbuminemia as an inde­pendent predictor of complications, critical illness and premature death. Russian Journal of Anesthesiology and Reanimatology. 2024;(4):83-89
Safety profile of pressurized intraperitoneal aero­sol chemotherapy in the treatment of ovarian cancer. P.A. Herzen Journal of Onco­logy. 2024;(5):25-30

Thrombolytic therapy is a highly effective method for restoring the patency of the lung arterial bed in the patients presenting with massive pulmonary embolism. At the same time, the application of fibrinolytic agents is fraught with the high risk of anaphylactic reactions and hemorrhages of differing severity. The present paper is a review of the literature data concerning the results and complications of thrombolytic therapy with the use of various fibrinolytic agents for the management of massive pulmonary embolism. The most common problems pertinent to the application of modern thrombolytic medicines are discussed. The comparative analysis of the frequency of development of "major" and "minor" hemorrhages associated with the use of fibrin-specific (tissue plasminogen activators) and fibrin-nonspecific (streptokinase, urokinase) preparations is undertaken. The analysis included the assessment of the relationship between the risk of the development of hemorrhagic complications and the mechanisms of action of thrombolytic preparations. The possibilities of using fibrinolytic agents in the patients at high risk of thrombolytic complications are considered with special reference to pharmacological cost effectiveness of thrombolysis for the treatment of the patients with massive pulmonary embolism.

Keywords:

pulmonary embolism
thrombolytic therapy
complications
urokinase
alteplase

Authors:

Leont'ev S.G.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Mironov A.V.

NII SP im. N.V. Sklifosovskogo

Ustinov F.S.

Gorodskaia klinicheskaia bol'nitsa #1 im. N.I. Pirogova, Moskva

List of references:

  1. Kucher N., Goldhaber S.Z. Management of massive pulmonary embolism. Circulation 2005; 112: e28-e32.
  2. Aujesky D., Jiménez D., Mor Maria K., Geng M., Fine M.J., Ibrahim S.A. Weekend versus weekday admission and mortality after acute pulmonary embolism. Circulation 2009; 119: 7: 962-968.
  3. Laporte S., Mismetti P., Décousus H., Uresandi F., Otero R., Lobo J. L., Monreal M. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117: 13: 1711-1716.
  4. Konstantinides S.V. Acute pulmonary embolism revisited. Thromboembolic venous disease. Heart 2008; 94: 795-802.
  5. Internet Communication. Available at: http://www.surgeongeneral.gov/news/pressreleases/pr20080915.html. Accessed May 01, 2012.
  6. Cohen A.T., Agnelli G., Frederick A., Arcelus J.I., Bergqvist D., Brecht J.G., Greer A., Heit J.A., Hutchinson J.L., Kakkar A.K., Mottier D., Oger E., Samama M., Spannagl M. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 4: 756-764.
  7. Cohen A.T., Edmondson R.A., Phillips M.J., Ward V.P., Kakkar V.V. The changing pattern of venous thromboembolic disease. Haemostasis 1996; 26: 2: 65-71.
  8. Lindblad B., Sternby N.H., Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991; 302: 6778: 709-711.
  9. Kasper W., Konstantinides S., Geibel A., Olschewski M., Heinrich F., Grosser K. D., Rauber K., Iversen S., Redecker M., Kienast J. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997; 30: 5: 1165-1171.
  10. British Thoracic Society Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992; 340: 8824: 873-876.
  11. Carson J.L., Kelley M.A., Duff A. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 19: 1240-1245.
  12. Aymard T., Kadner A., Widmer A., Basciani R., Tevaearai H., Weber A., Schmidli J., Carrel T. Massive pulmonary embolism: surgical embolectomy versus thrombolytic therapy - should surgical indications be revisited? Eur J Cardiothorac Surg 2012.
  13. Lehnert P., Müller C.H., Carlsen J., Grande P., Steinbrüchel D.A. Surgical treatment of acute pulmonary embolism-a 12-year retrospective analysis. Scand Cardiovasc J 2012.
  14. Gordon H., Guyatt M.D., Elie A., Mark C., David D., Gutterman H. J. Schuünemann Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: Issue 2: Suppl.
  15. Stein P.D., Matta F., Steinberger D.S., Keyes D.C. Intracerebral Hemorrhage with Thrombolytic Therapy for Acute Pulmonary Embolism. Am J Med 2012; 125: Issue 1.
  16. Gupta S., Gupta B.M. Acute pulmonary embolism advances in treatment. J Ass Physic India 2008; 56: 185-191.
  17. Konstantinides S.V. Massive pulmonary embolism: what level of aggression? Semin Respir Crit Care Med 2008; 29: 1: 47-55.
  18. Aklog L., Williams C.S., Byrne J.G., Goldhaber S.Z. Acute pulmonary embolectomy: a contemporary approach. Circulation 2002; 105: 1416-1419.
  19. Yalamanchili K., Fleisher A.G., Lehrman S.G., Axelrod H.I., Lafaro R.J., Sarabu M.R., Zias E.A., Moggio R.A. Open pulmonary embolectomy for treatment of major pulmonary embolism. Ann Thorac Surg 2004; 77: 819-823.
  20. Leacche M., Unic D., Goldhaber S.Z., Rawn J.D., Aranki S.F., Couper G.S., Mihaljevic T., Rizzo R.J., Cohn L.H., Aklog L., Byrne J.G. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg 2005; 129: 1018-1023.
  21. Torbicki A., Chairperson A.P., Konstantinides C., Agnelli G., Galie N., Pruszczyk P., Bengel F., Brady A.J.B., Ferreira D., Janssens U., Klepetko W., Mayer E., Martine Remy-Jardin, Jean-Pierre Bassand. et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2008; 29: 2276-2315.
  22. Tillett W. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58: 485-502.
  23. Browse N.L., James D.C. Streptokinase and pulmonary embolism. Lancet 1964; 2: 1039-1043.
  24. Lam S., Lee S., Chan K., Chan M., Hai Jo-Jo., Tam F., Wong M., Wong A., Yung A., Kong S.L., Lam L., Chan R. A 10-year review of thrombolytic therapy in patients with st-segment elevation myocardial infarction in a university hospital in Hong Kong-intracranial bleeding and other outcomes. J Am Coll Cardiol 2012; Suppl 159: 13.
  25. Janoušek S. Has Streptokinase Still a Place in Treatment of Acute Myocardial Infarction? Vnitrni Lekarstvi 2003; 49: 11: 880-884.
  26. Toquero J., Silva L. Allergic reaction to streptokinase. Revista española de cardiología 2001; 54: 10: 1225.
  27. Meneveau N., Vuillemenot A., Bassand J.P. Complications of thrombolytic therapy in pulmonary embolism. Archives des maladies du coeur et des vaisseaux 1995; 88: 11: Suppl: 1769-1776.
  28. Perler B. Thrombolytic therapies: the current state of affairs. J Endovasc Ther 2005; 12: 2: 224-232.
  29. Sharma G.V., Folland E.D. Long-term hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease. JACC 1990; 65A.
  30. Konstantinides S., Geibel A., Kasper W. Submassive and massive pulmonary embolism: a target for thrombolytic therapy? Thromb Haemost 1999; 82: Suppl 1: 104-108.
  31. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
  32. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
  33. Third International Study of Infarct Survival Collaborative Group. ISIS-3: a randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.
  34. Weitz J.I. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. J Vasc Interv Radiol 1995; 6: 19S-23S.
  35. Gurewich V. Fibrinolysis: an unfinished agenda. Blood Coagul Fibrinol 2000; 11: 401-408.
  36. Schafer K., Konstantinides S., Riedel C. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase or tissue-type plasminogen activator. Circulation 2002; 106: 1847-1852.
  37. Agnelli G., Becattini C. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 2002; 162: 2537-2541.
  38. Clark W.M., Wissman S., Albers G.W., Jhamandas J.H., Madden K.P., Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. JAMA 1999; 282: 2019-2026.
  39. Hacke W., Albers G., Al-Rawi Y., Bogousslavsky J., Davalos A., Fischer M., Furlan A., Kaste M.L., Kennedy R., Soehngen M., Warach S. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73.
  40. Chaitman B.R., Thompson B., Wittry M.D., Stump D., Hamilton W.P., Hillis L.D., Dwyer J.G., Solomon R.E., Knatterud G.L. The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: Results from Thrombolysis in Myocardial Infarction phase I, open label studies and the Thrombolysis in Myocardial Infarction phase II pilot study. J Am Coll Cardiol 1989; 14: 1159-1165.
  41. Kanter D.S., Mikkola K.M. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111: 1241-1245.
  42. Gürbüz Özlem Zeynep Öner, Fatma Alibaz., Akyay Ali Ilker., Coşkun Yusuf., Mecdi Ergüney et al. The results of streptokinase therapy in acute pulmonary embolism with intermediate and high risk. Turk Toraks Dergisi 2012; 13: 1: 6-10.
  43. Systemic thrombolysis in patients with acute ischemic stroke and internal carotid artery occlusion: The ICARO study. Stroke 2012; 1: 125-130.
  44. The UKEP study: Multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. Eur Heart J 1987; 8: 1: 2-10.
  45. Marini C., Di Ricco G., Rossi G., Rindi M., Palla R., Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolisma randomized clinical trial. Respiration 1988; 54: 162-173.
  46. The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation 1973; 47: Suppl II: II1-II108.
  47. Ly B., Arnesen H., Eie H., Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203: 465-470.
  48. Tibbutt D.A., Davies J.A., Anderson J.A., Fletcher E.W., Hamill J., Holt J.M., Thomas M.L., Lee G., Miller G.A., Sharp A.A., Sutton G.C. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J 1974; 1: 343-347.
  49. Miguel Ángel de Gregorio, Alicia Laborda, Ignacio de Blas, Joaquín Medrano, a Antonio Mainar, Mikel Oribe. et al. Endovascular Treatment of a Haemodynamically Unstable Massive Pulmonary Embolism using Fibrinolysis and Fragmentation. Experience with 111 Patients in a Single Centre. Why don't we follow ACCP Recommendations? Arch Bronconeumol 2011; 47: 1: 17-24.
  50. Yanzhou Z., Tongwen S., Ben He, Lexin W. Thrombolytic therapy with urokinase for pulmonary embolism in patients with stable hemodynamics. Med Sci Monit 2007; 13: 1: CR20-CR23.
  51. Hacke W., Kaste M., Fieschi C. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
  52. Chaitman B.R., Thompson B. The use of tissue-type plasminogenactivator for acute myocardial infarction in the elderly: Results fromThrombolysis in Myocardial Infarction phase I, open label studies and the Thrombolysis in Myocardial Infarction phase II pilot study. J Am Coll Cardiol 1989; 14: 1159-1165.
  53. Simoons M.L., Maggioni A.P., Knatterud G., Leimberger J.D., de Jaegere P., van Domburg R., Boersma E., Franzosi M.G., Califf R., Schröder R. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet 1993; 342: 1523-1528.
  54. Mikkola K.M., Patel S.R. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 1997; 134: 69-72.
  55. Goldhaber S.Z., Visani L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 9162: 1386-1389.
  56. Kanter D.S., Mikkola K.M. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111: 1241-1245.
  57. Meneveau N., Ming Liu Pin, Séronde M., Mersin N., Schiele F., Caulfield F., Bernard Y., Bassand J. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J 2003; 24: 1447-1454.
  58. Management Strategies and Determinants of Outcome in Acute Major Pulmonary Embolism; results of a multicenter registry (MAPPET). J Am Coll Cardiol 1997; 30: 1165-1171.
  59. Konstantinides S., Geibel A., Olschewski M., Heinrich F., Grosser K., Rauber K., Iversen S., Redecker M., Kienast J., Just H., Kasper W. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism. Circulation 1997; 96: 882-888.
  60. Tanne D., Gorman M.J., Bates V.E., Kasner S.E., Scott P., Verro Piero B., Jeffrey R., Dayno J., Schultz L.R., Levine S.R. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: The tPA stroke survey experience. Stroke 2000; 31: 370-375.
  61. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The multicenter rt-PA stroke survey. Circulation 2002; 105: 1679-1685.
  62. Simon J.E., Sandler D.L., Pexman J.H. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischemic stroke? The Calgary experience. Age Ageing 2004; 33: 143-149.
  63. Simoons M.L., Maggioni A.P, Knatterud G., Leimberger J.D., de Jaegere P., van Domburg R., Boersma E., Franzosi M.G., Califf R., Schröder R. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet 1993; 342: 1523-1528.
  64. Berrouschot J., Röther J., Glahn J., Kucinski T., Fiehler J., Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke 2005; 36: 2421-2425.
  65. Mouradian M.S., Senthilselvan A., Jickling G., McCombe J.A., Emery D.J., Dean N., Shuaib A. Intravenous rt-PA for acute stroke: Comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiat 2005; 76: 1234-1237.
  66. Engelter S.T., Bonati L.H., Lyrer P.A. Intravenous thrombolysis in stroke patients of > or=80 versus <80 years of age - a systematic review across cohort studies. Age Ageing 2006; 35: 572-580.
  67. Sylaja P.N., Cote R., Buchan A.M., Hill M.D. Thrombolysis in patients older than 80 years with acute ischemic stroke: Canadian alteplase for stroke effectiveness study. J Neurol Neurosurg Psychiat 2006; 77: 826-829.
  68. Pundik S., McWilliams-Dunnigan L., Blackham K.L., Kirchner H.L., Sundararajan S., Sunshine Jeffrey L., Tarr R.W., Selman W.R., Landis D., Suarez Jose I. Intra-arterial thrombolysis for acute stroke in patients 80 and older: A comparison of results in patients younger than 80 years. AJNR 2007; 28: 159-163.
  69. Thabut G., Thabut D., Myers R., Bernard-Chabert B., Marrash-Chahla R., Mal H., Fournier M. Thrombolytic therapy of pulmonary embolism: A meta-analysis. J Am Coll Cardiol 2006; 40: 9: 1660-1667.
  70. Capstick T., Henry M.T. Efficacy of thrombolytic agents in the treatment of pulmonary embolism. Eur Respir J 2005; 26: 864-874.
  71. Arcasoy S.M., Kreit J.W. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest 1999; 115: 1695-1707.
  72. Digonnet A., Moya-Plana A., Aubert S., Flecher E., Bonnet N., Leprince P., Pavie A., Gandjbakhch I. Acute pulmonary embolism: a current surgical approach. Interact Cardiovasc Thorac Surg 2007; 6: 27-29.
  73. Kucher N. Catheter embolectomy for acute pulmonary embolism. Chest 2007; 132: 657-663.
  74. Bulpa P., Carbutti G., Osselaer J., Lawson G., Dive A., Evrard P. Low-Dose Urokinase in Massive pulmonary Embolism When Standard Thrombolysis Is Contraindicated. Chest 2009;136: Issue 4.
  75. Klaus S., Bahlmann L., Mierisch C., Heringlake M., Schmucker P. Early postoperative thrombolytic therapy after laparotomy. Resuscitation 2001; 50: 353-355.
  76. Sayeed R.A., Nashef S.A. Successful thrombolysis for massive pulmonary embolism after pulmonary resection. Ann Thorac Surg 1999; 67: 1785-1787.
  77. Nakao M. Local low-dose infusion of streptokinase for massive pulmonary embolism when systemic thrombolysis is contraindicated. N Y State J Med 1990; 90: 32-33.
  78. Leeper K.V., Popovich J., Lesser B.A, Adams D., Froelich J.W., Burke M.W., Shetty P.C., Thrall J.H., Stein P.D. Treatment of massive acute pulmonary embolism: the use of low doses of intrapulmonary arterial streptokinase combined with full doses of systemic heparin. Chest 1988; 93: 234-240.
  79. Spöhr F., Rehmert G.C., Böttiger B.W., Hagl S., Gries A. Successful thrombolysis after pulmonary embolectomy for persistent massive postoperative pulmonary embolism. Resuscitation 2004; 62: 113-118.
  80. Vujic I., Young J.W., Gobien R.P., Dawson W.T., Liebscher L., Shelley B.E. Massive pulmonary embolism: treatment with full heparinization and topical low-dose streptokinase. Radiology 1983; 148: 671-675.
  81. Molina J.E., Hunter D.W., Yedlicka J.W., Cerra F.B. Thrombolytic therapy for postoperative pulmonary embolism. Am J Surg 1992; 163: 375-380.
  82. Bell R. Present-day thrombolytic therapy: therapeutic agents; pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med 2002; 3: Suppl: S34-S44.
  83. Meyer G., Gisselbrecht M., Diehl J., Journois D., Sors H. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998; 105: 472-477.
  84. Verstraete M., Miller G.A., Bounameaux H., Charbonnier B., Colle J.P, Lecorf G., Marbet G.A., Mombaerts P., Olsson C.G. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1998; 77: 353-360.
  85. Laaban J.P., Poubeau P., Horellou M.H., Ecoiffier J., Conard J., Rochemaure J. Value of moderate doses of urokinase combined with heparin in the treatment of massive pulmonary embolism: a retrospective study of 33 cases. Ann Med Inter (Paris) 1989; 140: 551-556.
  86. Hyers T., Hull R., Weg J.G. Antithrombotic therapy for venous thromboembolic disease. Chest 1992; 102: Suppl: 408S-425S.
  87. Hyers T., Agnelli G., Hull R.D., Weg J.G., Morris T.A., Samama M.M., Tapson V. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: Suppl: 176S-193S.
  88. Perler B. Thrombolytic therapies: the current state of affairs. J Endovasc Ther 2005; 12: 224-232.
  89. Schulman S., Lockner D., Granqvist S., Bratt G., Paul C., Nyman D. A comparative randomized trial of low-dose versus high-dose streptokinase in deep vein thrombosis of the thigh. Thromb Haemost 1984; 51: 261-265.
  90. Goldhaber S.Z., Agnelli G., Levine M.N. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis: an international multi-center randomized trial. Chest 1994; 106: 718-724.
  91. Sors H., Pacouret G., Azarian R., Meyer G., Charbonnier B., Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial. Chest 1994; 106: 712-717.
  92. Brian T., Fengler M.D., William J., Brady M.D. Fibrinolytic therapy in pulmonary embolism:an evidence-based treatment algorithm. Am J Emerg Med 2009; 27: 84-95.
  93. Ouriel K., Kaul A.F., Leonard M.C. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. J Vasc Surg 2004; 40: 971-977.
  94. Taylor T.N., Davis P.H., Torner J.C., Holmes J., Meyer J.W., Jacobson M.F. Lifetime cost of stroke in the United States. Stroke 1996; 27: 1459-1466.
  95. Zatevakhin I.I., Zolkin V.N., Krivtsov Yu.V. Tromboliticheskaya terapiya u bol'nykh s tromboemboliey legochnoy arterii i trombozom glubokikh ven. Angiol i sosud khir 2011; 17: 3.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.